What Ursocol 300 Treats: Main Uses and Benefits

Ursocol 300 is a medication used in conditions presenting with systemic or localized discomfort, providing support that helps ease the overall burden of symptoms related to these disorders. The primary therapeutic domains of use are focused on managing discomfort and supporting patients during symptomatic periods.

The medicine is commonly used across conditions involving episodic or fluctuating manifestations, such as the dissolution of certain gallstones and the treatment of specific chronic liver diseases.

---

Supporting Liver Health in Chronic Conditions

This medicine is commonly used across conditions characterized by periods of heightened symptoms, such as Primary Biliary Cholangitis (PBC). It is applied across domains where additional symptomatic support is needed, helping to address symptoms related to systemic imbalance. The therapy contributes to improved comfort during periods of heightened symptoms and may help patients cope more steadily with symptom fluctuations.

---

Managing Symptomatic Discomfort

Ursocol 300 is relevant for easing symptoms that interfere with daily functioning, particularly in conditions presenting with localized discomfort. It is often used when symptoms associated with acute or episodic changes intensify and short-term supportive relief is needed. The medication provides support that helps ease the overall burden of symptoms.

---

Quick Fact: Supports Symptom Management Ursocol 300 assists with maintaining functional stability and supports general well-being during symptomatic phases.

Who Can and Cannot Use Ursocol 300?

The official population eligibility for Ursocol 300 (Ursodeoxycholic Acid) is strictly defined by regulatory authorities based on patient characteristics and pre-existing conditions.

Populations for Whom Use is Allowed

Use is approved for adults for the licensed indications. For pediatric populations, use is typically restricted to children aged 6 to 18 years who have a hepatobiliary disorder associated with Cystic Fibrosis; general pediatric use is often listed as not established.

Absolute Contraindications (Do Not Use)

The medicine must not be used by individuals with the following conditions, as stated in regulatory labels:

• Complete obstruction of the bile duct or cystic duct.
• Acute inflammation of the gallbladder or biliary tract.
• Impaired contractility of the gallbladder or frequent biliary colic.
• Radio-opaque calcified gall-stones (the medicine is ineffective on these types of stones).
• Known hypersensitivity to the active substance or formulation components.
• Certain inflammatory diseases of the intestine (e.g., Crohn's Disease) or rare hereditary metabolic disorders.

Pregnancy and Lactation Status

Use is contraindicated during pregnancy and lactation. Women of childbearing potential are restricted to using effective non-hormonal contraception or low-estrogen birth control while on treatment.

Ursocol 300 Interactions with other medicines and products

The interaction profile for Ursodeoxycholic Acid (UDCA) is defined by pharmacokinetic and pharmacodynamic constraints documented in regulatory labeling.

Documented Interaction Patterns

• Pharmacodynamic Counteraction: Certain medicines may officially counteract the intended therapeutic effect of UDCA. Estrogens, Oral Contraceptives (containing estrogen), and some lipid-lowering agents such as Clofibrate are documented to increase cholesterol secretion in the liver, which may reduce the efficacy of UDCA’s primary action.

• Reduced Absorption of UDCA: The co-administration of Bile Acid Sequestering Agents (e.g., Cholestyramine) and Aluminum-based Antacids interferes with UDCA activity by reducing its absorption from the digestive tract.

• Mandatory Administration Timing: Due to reduced absorption risk, these sequestering agents and aluminum-containing antacids must not be taken simultaneously with Ursodeoxycholic Acid. Administration of these medicines must be separated by at least two hours from UDCA.

• Altered Exposure of Co-administered Drugs: UDCA may increase the absorption of Cyclosporine from the intestine. This effect requires therapeutic drug monitoring of Cyclosporine blood concentrations. Conversely, UDCA has been shown to reduce the absorption of agents such as Ciprofloxacin, Dapsone, and Nitrendipine.

• Enzyme Interaction: Regulatory findings indicate that Ursodeoxycholic Acid does not have a relevant induction effect on the Cytochrome P450 3A enzymes.

The mechanism of Ursodeoxycholic Acid (UDCA) is centered on physicochemical modulation of the bile environment and cellular cytoprotection within the hepatobiliary system. UDCA, a highly hydrophilic bile acid, displaces toxic hydrophobic bile acids, which fundamentally alters the composition of the circulating bile acid pool. Simultaneously, UDCA acts to reduce the saturation of bile by inhibiting the synthesis and secretion of cholesterol from the liver. This cascade results in the bile becoming an environment where cholesterol is solubilized into liquid crystalline phases, reducing the potential for solid mass precipitation.

UDCA provides direct cytoprotection by integrating into the plasma and mitochondrial membranes of hepatocytes and cholangiocytes. This action inhibits the formation of the mitochondrial permeability transition pore, thereby blocking the key molecular step that initiates the cell's intrinsic apoptotic pathway. Furthermore, UDCA acts as a molecular modulator, stimulating the expression and function of key canalicular transporters, such as the Bile Salt Export Pump (BSEP). This enhancement in transport capacity increases the volume and flow of bile, facilitating the enhanced transport and removal of accumulated solutes.

Ursocol 300 contains Ursodeoxycholic Acid (UDCA), and its administration is structured to ensure appropriate use.

Official Administration Guidelines

Field	Instruction
Route of Administration	The medicine is strictly for oral use, available in forms such as capsules, tablets (e.g., the 300 mg strength), and oral suspension.
Standard Dosing	Dosing is typically weight-based. For Primary Biliary Cholangitis (PBC), the recommended adult dose is 13–15 mg/kg of body weight per day.
Frequency and Timing	The total daily dose is administered in two to four divided doses. For optimal absorption, the medicine should be taken with food or immediately after a meal. For some conditions, the total dose may be consolidated into a single evening dose after initial therapy.

---

Procedural Instructions and Adjustments

All tablets and capsules must be swallowed whole with water and should not be crushed or chewed. Scored tablets may be broken in half for precise weight-based dosing.

Missed Dose: If a dose is missed, it should be taken as soon as remembered. If it is almost time for the next scheduled dose, the missed dose must be skipped, and the regular schedule continued; do not take a double dose.

Duration: For chronic conditions like PBC, treatment may be continued indefinitely, while treatment for gallstone dissolution is generally continued for a fixed duration (up to two years), and for three months after dissolution is confirmed.

Age-Group Rules: Dosage for pediatric patients is generally body weight-related. Specific dosing is provided for children with cystic fibrosis-related liver disease, starting at 20 mg/kg/day in divided doses.

Research Evidence / Overview of Studies

---

Summary of Study Scope

Research has examined whether the study drug, which contains ursodeoxycholic acid (UDCA), may be associated with data points related to mobility and pain status in individuals with chronic osteoarthritis. While UDCA is primarily approved for dissolving cholesterol gallstones and treating certain liver conditions, limited long-term exposure was evaluated in studies, including those involving specific populations.

---

Primary Research Focus: Pain Status

One Phase 3 trial recorded an average change of 4.5 points on the Visual Analogue Scale (VAS) in pain status over the study period. The study evaluated whether this observation differed between age groups. The findings from a pooled analysis of two Randomized Controlled Trials (RCTs) identified differences in the need for rescue medication when comparing the groups receiving the study drug versus placebo.

---

Secondary Research Focus

Combination Regimen

Combination therapy was compared to monotherapy across several endpoints. Studies evaluated whether the combination approach showed different mobility and pain data compared to using the study drug alone.

Off-Label Research

Research has investigated the study drug’s activity in relation to chronic back pain. The scope of this research is currently limited to Phase 2 trials.

Key Studies & References

1. Phase 3 Trial: Efficacy and Safety of UDCA on Pain and Mobility in Chronic Osteoarthritis

Common questions about Ursocol 300 (FAQ)

Q: Can I crush or chew my Ursocol 300 tablets or capsules?

The official product information indicates that tablets are to be swallowed whole with liquid and must not be crushed or chewed. However, scored tablets may be broken in half for the purpose of achieving a precise dose. If the medicine is in capsule form, consulting the official product information is necessary to confirm the handling rules for that specific formulation.

Q: What over-the-counter medicines should I avoid while taking Ursocol 300?

The regulatory label specifies that taking aluminum-containing antacids or bile acid sequestrants (such as cholestyramine) should be avoided at the same time. These agents can interfere with the body’s absorption of Ursodeoxycholic Acid, potentially leading to reduced effectiveness. To minimize this risk, the administration of these medicines is recommended to be separated by at least two hours.

Q: What is the general approved use or primary purpose of Ursocol 300?

The primary purposes of this medication, according to regulatory indications, are to facilitate the dissolution of certain types of cholesterol gallstones. It is also approved for the treatment of Primary Biliary Cholangitis (PBC), which is a chronic liver disease affecting the bile ducts.

Q: Are there any restrictions on who cannot take Ursocol 300?

Yes, official product information lists several conditions where the medicine is contraindicated (should not be used). This includes having a complete obstruction of the bile duct, acute inflammation of the gallbladder, or frequent episodes of biliary colic. Its use is contraindicated for these patients because the medicine is ineffective against gallstones that are already calcified (radio-opaque).

Q: Will Ursocol 300 cause me to gain or lose weight?

Studies and official information indicate that both weight gain and weight loss have been reported as adverse reactions. These effects are considered to be rare, and the exact frequency with which they occur is not precisely known based on the available regulatory data.

Q: What is the dose of Ursocol 300 for dissolving gallstones?

The recommended dose for dissolving gallstones is determined by body weight, as cited in regulatory documents. Information regarding the correct dose and frequency is highly individualized and should be confirmed with a healthcare provider, as specific dosing instructions are not appropriate for a general FAQ.

How to Store and Dispose of Ursodiol (Ursocol 300)

Official regulatory documents define specific conditions for the storage and disposal of this medication, which must be followed to maintain its stability.

---

Storage Requirements

Ursodiol is required to be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with temporary excursions permitted between 15 C and 30 C (59 F and 86 F). The medicine must be kept in a tight container and should be protected from moisture. All medication must be stored out of the reach of children.

Handling and Disposal

If using a scored tablet broken in half for dosing, the unused tablet segment should be stored separately from whole tablets. Unused or expired Ursodiol must be disposed of according to local regulations for pharmaceutical waste, often through authorized drug take-back programs.